MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Novo Nordisk A/S Company Profile (NYSE:NVO)

Consensus Ratings for Novo Nordisk A/S (NYSE:NVO) (?)
Ratings Breakdown: 2 Hold Rating(s), 2 Buy Rating(s), 2 Strong Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $56.00 (9.67% upside)

Analysts' Ratings History for Novo Nordisk A/S (NYSE:NVO)
Show:
DateFirmActionRatingPrice TargetActions
4/1/2016Citigroup Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/15/2016Goldman SachsUpgradeBuy -> Conviction-BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/26/2016Oddo SecuritiesUpgradeNeutral -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/21/2015SwedbankUpgradeStrong-BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/28/2015Leerink SwannInitiated CoverageMarket Perform$56.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/10/2015Main First Bank AGDowngradeHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/25/2015HSBCInitiated CoverageReduceView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2015Morgan StanleyUpgradeEqual Weight -> OverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/15/2015Societe GeneraleInitiated CoverageSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/26/2015Bryan, Garnier & CoDowngradeNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/29/2015Commerzbank AGDowngradeHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/25/2014BNP ParibasInitiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Novo Nordisk A/S (NYSE:NVO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
4/29/2016Q1$0.53$0.57ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2015Q3$0.47$0.48ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215$3.31$3.23$3.98 billion$27.06 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q1$3.20$3.02$25.13 billion$25.20 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/30/2015Q4$2.48$0.38$24.67 billion$24.59 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2014Q3$2.45$2.47$22.25 billion$22.25 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q2$2.60$0.48$21.86 billion$21.63 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2014Q1$2.37$2.43$20.83 billion$20.30 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/28/2014Q413$0.42ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2013Q1$12.11$2.20$21.04 billion$20.51 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q1$11.97$12.45$21.09 billion$21.38 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2013$10.67$10.98$19.73 billion$19.98 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/31/2013$9.77$10.53$20.83 billion$20.96 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2012Q312$9.43$10.33$57.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Novo Nordisk A/S (NYSE:NVO)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.39$0.53$0.48
Q2 20163$0.42$0.56$0.51
Q3 20163$0.44$0.57$0.52
Q4 20163$0.46$0.60$0.55
(Data provided by Zacks Investment Research)
Current Dividend Information for Novo Nordisk A/S (NYSE:NVO)
Annual Dividend:$0.70
Dividend Yield:1.37%
Payout Ratio:29.91%
Dividend Growth:13.30% (3 Year Average)

Dividend History for Novo Nordisk A/S (NYSE:NVO)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
2/16/2016Annual$0.703/18/20163/22/20163/30/2016Tweet This Announcement  Share This Announcement on StockTwits
3/17/2014annual$0.841.83%3/21/20143/25/20144/2/2014Tweet This Announcement  Share This Announcement on StockTwits
2/27/2013annual$3.181.81%3/21/20133/25/20134/2/2013Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)
Insider Trading History for Novo Nordisk A/S (NYSE:NVO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
2/18/2015Richmond Partners Master LimitInsiderSell24,900$1.28$31,876.98Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Novo Nordisk A/S (NYSE:NVO)
DateHeadline
06/23/16 06:03 PMHC Stocks Momentum: Novo Nordisk A/S (ADR) (NYSE:NVO), St. Jude Medical, Inc. (NYSE:STJ) - share market updates (press release)
06/23/16 06:03 PMRecommendation Trends for: Novo Nordisk A/S (NYSE:NVO) - News Oracle
06/22/16 10:17 AMNovo Nordisk A/S (NYSE:NVO) Analyst Rating Consensus - TheFounders Daily
06/20/16 07:38 AMWhat Is It About Novo Nordisk's Diabetes Drug That Makes It a Top Seller? -
06/20/16 07:11 AMNovo Nordisk A/S (NYSE:NVO) headlining after earnings
06/20/16 07:09 AMNovo Nordisk A/S - aktietilbagekøbsprogram - [at noodls] - Information about cookies A cookie is a small text file, which is placed on your computer or other device. It makes it possible for us to recognize your computer and gather information about which pages ...
06/17/16 05:23 PMLarge Inflow of Money Witnessed in Novo Nordisk A/S
06/17/16 05:23 PMStock in the Spotlight: Novo Nordisk A/S (NYSE:NVO)
06/17/16 08:20 AMEarnings Expectations Overview: Novo Nordisk A/S (NYSE:NVO), The Dow Chemical Company (NYSE:DOW) - Beacon Chronicle
06/16/16 05:33 PMWhy This Pharma Giant Lost $8 Billion in Market Cap This Week -
06/16/16 09:46 AMNovo-Nordisk is Oversold
06/15/16 05:31 PMNovo Nordisk A/S (ADR) (NYSE:NVO) Victoza Reduces Cardiovascular Risks - Market Exclusive
06/15/16 02:17 PMNovo Nordisk (NVO) Reports Positive Trial Results on Victoza -
06/15/16 10:07 AMOne should look at these two Stocks: Novo Nordisk A/S (NYSE:NVO), CF Industries Holdings, Inc. (NYSE:CF) - Beacon Chronicle
06/15/16 10:07 AMTrade-Ideas: Novo Nordisk A/S (NVO) Is Today's Pre-Market Mover With Heavy Volume Stock - TheStreet.com
06/14/16 05:17 PMNovo-Nordisk is Oversold - Nasdaq
06/14/16 05:17 PMWhy American Airlines Group Inc (AAL), Novo Nordisk A/S (ADR) (NVO) and Synchrony Financial (SYF) Are 3 of ... - Investorplace.com
06/14/16 12:13 PMWorst Performing Industries For June 14, 2016 - The Dow fell 0.52 percent to 17,639.76, while the NASDAQ composite index declined 0.42 percent to 4,828.30. The broader Standard & Poor's 500 index dropped 0.47 percent to 2,069.30. The worst performing industries in the market today are: Drug Manufacturers - Other: This industry slipped 2.2 percent by 11:00 am. The worst stock within the industry was Novo Nordisk A/S (ADR) (NYSE: NVO), ...Full story available on Benzinga.com
06/13/16 05:07 PMHC Stocks Outlines: Novo Nordisk A/S (NVO), Biogen Inc (BIIB) - share market updates (press release)
06/13/16 05:07 PMTwo Movers within Analysts Observation: MannKind Corporation (NASDAQ:MNKD) , Novo Nordisk A/S (NYSE:NVO) - Street Updates
06/13/16 05:07 PMPerformance watch list: Novo Nordisk A/S (NVO) - News Oracle
06/13/16 08:30 AMBuy Sell or Hold? - Novo Nordisk A/S (NYSE:NVO), Prudential Financial, Inc. (NYSE:PRU) - Beacon Chronicle
06/10/16 08:29 AMStocks Showing Momentum: NXP Semiconductors NV (NASDAQ:NXPI), Novo Nordisk A/S (NYSE:NVO) - Beacon Chronicle
06/09/16 05:53 PMBest Stocks for Investors: Spirit Airlines, Inc. (NASDAQ:SAVE), Novo Nordisk A/S (NYSE:NVO) - Beacon Chronicle
06/09/16 05:46 PMWall Street ‘Obesity’ Fund Could Make Your Wallet Fatter -
06/08/16 05:58 PMAnalyst Earnings Report: Novo Nordisk A/S (NYSE:NVO), PDL BioPharma, Inc. (NASDAQ:PDLI) - Beacon Chronicle
06/06/16 09:14 AMFisher Asset Management LLC Decreased Stake in Novo (NYSE:NVO) by $15.04 Million as Shares Declined - CCH Daily News
06/02/16 05:56 PMNovo Nordisk A/S (NYSE:NVO) Stock Update & Estimates - Stock Tick Tock - Novo Nordisk A/S (NYSE:NVO) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Novo Nordisk A/S (NYSE:NVO) to post earnings of $0.57 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be issued around ...and more »
06/02/16 08:31 AMAnalyst Earnings Report: Novo Nordisk A/S (NYSE:NVO), Starz (NASDAQ:STRZA) - Beacon Chronicle - Beacon ChronicleAnalyst Earnings Report: Novo Nordisk A/S (NYSE:NVO), Starz (NASDAQ:STRZA)Beacon ChronicleLast Trade: The Company closed its last session at $27.4 with the gain of 1.48%. The market capitalization of the company is $2.63 Billion, with the average Volume of 882.43K. The stock currently has its 52-Week High range of $46.59 and 52-week low ...and more »
06/01/16 06:03 PMAnalyst Earnings Report: Mobile TeleSystems PJSC (MBT), Novo Nordisk A/S (NVO) - Beacon Chronicle - Beacon ChronicleAnalyst Earnings Report: Mobile TeleSystems PJSC (MBT), Novo Nordisk A/S (NVO)Beacon ChronicleNovo Nordisk A/S (NYSE:NVO) currently has High Price Target of $60.1. The Low and Mean Price Targets are $60.1 and $60.1 respectively. These price targets are a consensus analysis of 1 brokers. When having a look at Recommendation Trends of the ...and more »
06/01/16 08:56 AMNovo Nordisk (NVO) Reports Positive Data on Diabetes Drug -
06/01/16 08:29 AMHC Stocks Judgment: Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), Novo Nordisk A/S (ADR) (NYSE:NVO) - share market updates (press release) - HC Stocks Judgment: Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), Novo Nordisk A/S (ADR) (NYSE:NVO)share market updates (press release)Shares of Novo Nordisk A/S (ADR) (NYSE:NVO) ended Tuesday session in green amid volatile trading. The shares closed up +0.60 points or 1.08% at $56.04 with 3.65 million shares getting traded. Post opening the session at $55.56, the shares hit an ...and more »
05/31/16 09:29 AMWeekly Biotech Report Covering Novo Nordisk A/S (NYSE:NVO) - Market Exclusive - Weekly Biotech Report Covering Novo Nordisk A/S (NYSE:NVO)Market ExclusiveThe final week of May saw a flurry of activity – and inactivity in one case – from the FDA for 7 different companies. Most of these companies have been covered in previous Market Exclusive Weekly Biotech Reports. Here we will review what happened last ...and more »
05/30/16 02:10 AMSemaglutide demonstrated superior glycaemic control vs insulin glargine U100 in adults with type 2 diabetes - [at noodls] - c70f81e1-8c35-4a59-a84a-8910c54c7408.pdf This material is intended for global medical media only. For journalistic assessment and preparation before publication. ... This is an abstract of the original ...
05/27/16 11:17 PMNovo Nordisk A/S (ADR) Rises on FDA Panel’s Positive Vote for Diabetes Combo - as it extends its reach in the fast expanding diabetes market Novo Nordisk A/S (ADR) (NYSE:NVO) is set to extend its dominance as the largest insulin maker among drug makers. The advisory panel of the US Food and Drug Administration has passed a positive ...
05/27/16 06:09 PMEarnings Review and Stock Rundown for Novo Nordisk A/S (NYSE:NVO) - Wall Street Hints and News - Earnings Review and Stock Rundown for Novo Nordisk A/S (NYSE:NVO)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Novo Nordisk A/S (NYSE:NVO) to post ...and more »
05/26/16 05:59 PMAnalysts Bullish on Novo Nordisk A/S (NYSE:NVO) - Stock Tick Tock - Analysts Bullish on Novo Nordisk A/S (NYSE:NVO)Stock Tick TockWall Street analysts have given a consensus Buy rating on shares of Novo Nordisk A/S (NYSE:NVO). Using the following ratings scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell and 5.0 Strong Sell, analysts have an average recommendation of 1.00 on the ...and more »
05/25/16 03:32 PMU.S. panel backs approval of Sanofi combination diabetes drug - [Reuters] - One day after recommending approval of a new diabetes drug made by Novo Nordisk A/S, a U.S. advisory panel on Wednesday recommended approval of a similar product made by Sanofi SA. The panel voted 12-2, with one person not voting, that the Food and Drug Administration should approve Sanofi's combination drug, iGlarLixi, for patients with type 2 diabetes. The agency is not obliged to follow the advice of its advisory panels but typically does so.
05/25/16 09:12 AMLatest Analyst Ratings For Novo Nordisk A/S (NYSE:NVO) - Share Trading News - Latest Analyst Ratings For Novo Nordisk A/S (NYSE:NVO)Share Trading News03/29/2016 – Novo Nordisk A/S had its “buy” rating reiterated by analysts at Citigroup. 02/08/2016 – Novo Nordisk A/S was downgraded to “sell” by analysts at UBS. 08/28/2015 – Leerink Swann began new coverage on Novo Nordisk A/S giving the company ...and more »
05/25/16 02:16 AMIDegLira receives positive 16-0 vote in favour of approval from FDA Advisory Committee - [at noodls] - company announcement Bagsværd, Denmark, 24 May 2016 - Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) voted ...
05/24/16 11:03 PMTarget Check and Stock Performance Recap Novo Nordisk A/S (NYSE:NVO) - Wall Street Hints and News - Target Check and Stock Performance Recap Novo Nordisk A/S (NYSE:NVO)Wall Street Hints and NewsTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Novo Nordisk A/S ...
05/24/16 03:27 PMU.S. FDA panel recommends approval of Novo Nordisk diabetes drug - [Reuters] - A U.S. advisory panel on Tuesday recommended approval of a new diabetes drug made by Novo Nordisk A/S that combines two of its existing treatments in a fixed-dose combination designed to be both effective ...
05/23/16 05:52 PMNoteworthy Stocks: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) , Novo Nordisk A/S (NYSE:NVO) - Street Updates - Noteworthy Stocks: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) , Novo Nordisk A/S (NYSE:NVO)Street UpdatesIn the past trading session, Novo Nordisk A/S (NYSE:NVO) highlighted upward shift of +0.41% or +0.22 points to $53.92. The company traded a volume of 1.02 million shares under average volume of 1.29 million shares. Trailing twelve month period, the ...and more »
05/23/16 08:18 AMFDA Staff Questions Usefulness of Sanofi’s Diabetes Drug Combo -
05/22/16 10:27 PMNext Weeks Broker Price Targets For Novo Nordisk A/S (NYSE:NVO) - Share Trading News - Next Weeks Broker Price Targets For Novo Nordisk A/S (NYSE:NVO)Share Trading News03/29/2016 – Novo Nordisk A/S had its “buy” rating reiterated by analysts at Citigroup. 02/08/2016 – Novo Nordisk A/S was downgraded to “sell” by analysts at UBS. 08/28/2015 – Leerink Swann began new coverage on Novo Nordisk A/S giving the company ...
05/22/16 10:27 PMStock Rating Review for Novo Nordisk A/S (NYSE:NVO) - Wall Street Hints and News - Stock Rating Review for Novo Nordisk A/S (NYSE:NVO)Wall Street Hints and NewsCovering equity analysts presently have a consensus stock rating of 2 on shares of Novo Nordisk A/S (NYSE:NVO). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research. This consensus rating is compiled ...and more »
05/20/16 05:49 PMShare Recap and Earnings Focus on Novo Nordisk A/S (NYSE:NVO) - Wall Street Hints and News - Share Recap and Earnings Focus on Novo Nordisk A/S (NYSE:NVO)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating Novo Nordisk A/S ...and more »
05/20/16 09:30 AMNotable Stocks within Investor Radar Novo Nordisk A/S (NYSE:NVO) , Illumina, Inc. (NASDAQ:ILMN) - Street Updates - Notable Stocks within Investor Radar Novo Nordisk A/S (NYSE:NVO) , Illumina, Inc. (NASDAQ:ILMN)Street UpdatesNovo Nordisk A/S (NYSE:NVO) diminished -1.13%, closing at $54.25 after floating between $54.14 and $54.76. The company has market capitalization of $138.03B. It has twelve month low of $46.17 and twelve month high of $60.34. The recent traded ...Novo Nordisk A/S (NYSE:NVO) Reports Basic Consolidated EPS At $1.8013Investor NewswireNovo Nordisk A/S (NYSE:NVO) topped earnings-per-share estimates 33% of the timeZergwatchNovo Nordisk A/S (NYSE:NVO) Updated Broker RatingsRisers & FallersCCH Daily Newsall 7 news articles »
05/20/16 07:53 AMFDA posts briefing materials prior to Advisory Committee meeting for IDegLira, a fixed combination product of insulin degludec and liraglutide - [at noodls] - company announcement Bagsværd, Denmark, 20 May 2016 - Novo Nordisk announced today that the US Food and Drug Administration (FDA) has published the briefing documents ahead of the 24 May 2016 Advisory ...
05/20/16 07:50 AMFDA staff question utility of Novo Nordisk combo diabetes drug - [Reuters - UK Focus] - A preliminary review by the U.S. Food and Drug Administration of Novo Nordisk A/S's experimental diabetes drug, IDegLira, questioned the interpretability of the study findings and practical utility of ...
About Novo Nordisk A/S

Novo Nordisk A/S logoNovo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It has a range of diabetes product portfolio, including a portfolio of modern insulins as well as a human once-daily GLP-1 analog. It operates in two segments: diabetes care and biopharmaceuticals. The Company's diabetes care segment covers insulins, GLP-1, other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. Its biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy and hormone replacement therapy. The primary production facilities owned by the Company are located at a number of sites in Denmark, and internationally in the United States, France, China and Brazil.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: NVO
  • CUSIP:
Key Metrics:
  • Previous Close: $51.06
  • 50 Day Moving Average: $54.41
  • 200 Day Moving Average: $54.64
  • P/E Ratio: 25.12
  • P/E Growth: 1.99
  • Market Cap: $129.91B
  • Current Quarter EPS Consensus Estimate: $2.29 EPS
Additional Links:
Novo Nordisk A/S (NYSE:NVO) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha